PE20120766A1 - Derivados de quinoxalina como inhibidores de tumores - Google Patents

Derivados de quinoxalina como inhibidores de tumores

Info

Publication number
PE20120766A1
PE20120766A1 PE2011001740A PE2011001740A PE20120766A1 PE 20120766 A1 PE20120766 A1 PE 20120766A1 PE 2011001740 A PE2011001740 A PE 2011001740A PE 2011001740 A PE2011001740 A PE 2011001740A PE 20120766 A1 PE20120766 A1 PE 20120766A1
Authority
PE
Peru
Prior art keywords
substituted
alkyl
quinoxalin
urea
halogen
Prior art date
Application number
PE2011001740A
Other languages
English (en)
Inventor
Matthias Gerlach
Irene Seifelt
Eckhard Gunther
Tillmann Schuster
Emmanuel Polymeropoulos
Michael Czech
Eckhard Claus
Original Assignee
Aeterna Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeterna Zentaris Gmbh filed Critical Aeterna Zentaris Gmbh
Publication of PE20120766A1 publication Critical patent/PE20120766A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE X ES O,S; R1 ES H, ALQUILO C1-C12 SUSTITUIDO O NO, CIANO, HALOGENO; R2 Y R3 SON CADA UNO H, ALQUILO C1-12 SUSTITUIDO O NO; R4 ES H, CICLOALQUILO SUSTITUIDO O NO, HETEROCICLILO SUSTITUIDO O NO; ALQUILARILO SUSTITUIDO O NO, ENTRE OTROS; R5, R6, R7 Y R8 SON CADA UNO H, ALQUILO C1-C12 SUSTITUIDO O NO, ARILO SUSTITUIDO O NO, HETEROARILO SUSTITUIDO O NO, HALOGENO, AMINO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-CICLOPENTIL-3-[7-(4-HIDROXI-3-METOXIFENIL)QUINOXALIN-2-IL]UREA; 1-[7-(3,4-DIMETOXIFENIL)QUINOXALIN-2-IL]-3-[1-(2,2,2-TRIFLUOROACETIL)PIPERIDIN-4-IL]UREA; ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE ADEMAS BLEOMICINA, CARBOPLATINO, EPIRUBICINA, IRINOTECAN, VINCRISTINA, ENTRE OTROS, SIENDO UTIL EN EL TRATAMIENTO DE CARCINOMAS METASTASICOS
PE2011001740A 2009-04-02 2010-03-25 Derivados de quinoxalina como inhibidores de tumores PE20120766A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16595309P 2009-04-02 2009-04-02
EP09157141A EP2241557A1 (de) 2009-04-02 2009-04-02 Chinoxalin-Derivate und deren Anwendung zur Behandlung gutartiger und bösartiger Tumorerkrankungen

Publications (1)

Publication Number Publication Date
PE20120766A1 true PE20120766A1 (es) 2012-07-19

Family

ID=40886691

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001740A PE20120766A1 (es) 2009-04-02 2010-03-25 Derivados de quinoxalina como inhibidores de tumores

Country Status (20)

Country Link
US (1) US8394801B2 (es)
EP (2) EP2241557A1 (es)
JP (1) JP5583201B2 (es)
KR (1) KR20110136888A (es)
CN (1) CN102378758A (es)
AR (1) AR075935A1 (es)
AU (1) AU2010233983A1 (es)
BR (1) BRPI1010306A2 (es)
CA (1) CA2757138A1 (es)
CO (1) CO6501171A2 (es)
EC (1) ECSP11011363A (es)
IL (1) IL215025A0 (es)
MX (1) MX2011010329A (es)
NZ (1) NZ595064A (es)
PE (1) PE20120766A1 (es)
RU (1) RU2532914C2 (es)
SG (1) SG175014A1 (es)
TW (1) TWI464150B (es)
UA (1) UA105211C2 (es)
WO (1) WO2010115719A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464675A (zh) * 2010-11-12 2012-05-23 上海医药工业研究院 具有抗肿瘤活性的金络合物及其可药用衍生物
BR112014001714A2 (pt) 2011-07-26 2017-02-14 Gruenenthal Gmbh derivados de carboxamida e ureia aromáticos bicíclicos substituídos como ligantes de receptor vaniloide
CN108137514A (zh) 2015-07-30 2018-06-08 百时美施贵宝公司 芳基取代的二环杂芳基化合物
JP7160688B2 (ja) * 2016-05-24 2022-10-25 ジェネンテック， インコーポレイテッド Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
CN110698418B (zh) * 2019-09-11 2022-07-01 广西师范大学 一种3-芳胺基喹喔啉-2-甲酰胺类衍生物及其制备方法和应用
CN115463217B (zh) * 2021-06-11 2024-03-12 深圳埃格林医药有限公司 己酸羟孕酮在增强肿瘤治疗效果中的应用
CN114605391B (zh) * 2022-02-21 2024-01-26 广州六顺生物科技股份有限公司 喹喔啉类衍生物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN842196A0 (en) 1996-03-05 1996-03-28 Fujisawa Pharmaceutical Co., Ltd. New compound
CA2291750A1 (en) 1997-05-28 1998-12-03 Rhone-Poulenc Rorer Pharmaceuticals Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6180632B1 (en) 1997-05-28 2001-01-30 Aventis Pharmaceuticals Products Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6159978A (en) 1997-05-28 2000-12-12 Aventis Pharmaceuticals Product, Inc. Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
NZ508280A (en) 1998-06-01 2002-09-27 Shionogi & Co 2- or 3-cyanoiminoquinoxaline derivatives useful as glutamate receptor antagonists
UA76977C2 (en) * 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
US7202244B2 (en) * 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
WO2008015423A1 (en) 2006-08-01 2008-02-07 Sentinel Oncology Limited Quinoline and quinoxaline n-oxides as chk-1 inhibitors
EP2150255A4 (en) 2007-05-10 2011-10-05 Glaxosmithkline Llc CHINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS
EP1990342A1 (en) * 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof

Also Published As

Publication number Publication date
RU2011138477A (ru) 2013-05-10
NZ595064A (en) 2013-10-25
CN102378758A (zh) 2012-03-14
JP5583201B2 (ja) 2014-09-03
WO2010115719A1 (en) 2010-10-14
JP2012522741A (ja) 2012-09-27
BRPI1010306A2 (pt) 2017-05-16
MX2011010329A (es) 2011-10-17
KR20110136888A (ko) 2011-12-21
UA105211C2 (ru) 2014-04-25
IL215025A0 (en) 2011-11-30
US20100266538A1 (en) 2010-10-21
ECSP11011363A (es) 2011-10-31
CA2757138A1 (en) 2010-10-14
US8394801B2 (en) 2013-03-12
EP2241557A1 (de) 2010-10-20
CO6501171A2 (es) 2012-08-15
RU2532914C2 (ru) 2014-11-20
EP2419411A1 (en) 2012-02-22
SG175014A1 (en) 2011-11-28
AU2010233983A1 (en) 2011-10-06
AR075935A1 (es) 2011-05-04
TWI464150B (zh) 2014-12-11
TW201100391A (en) 2011-01-01

Similar Documents

Publication Publication Date Title
PE20120766A1 (es) Derivados de quinoxalina como inhibidores de tumores
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20130647A1 (es) Indoles
PE20050087A1 (es) Derivados de 2-oxodihidropiridina n-sustituidos
PE20121282A1 (es) Antagonistas de espiro-oxindol de mdm2
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20090237A1 (es) Derivados de sulfonamidas como inhibidores de los canales de sodio
PE20090718A1 (es) Derivados de espiroindolinona
PE20130229A1 (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cancer
PE20190175A1 (es) Compuestos de pirrolotriazina como inhibidores de tam
PE20090709A1 (es) Compuestos heterociclico de 5 miembros
PE20142185A1 (es) Pirrolidina-2-carboxamidas sustituidas
PE20090610A1 (es) Derivados de pirazol sustituidos
PE20121010A1 (es) Derivados de bencimidazol
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20060383A1 (es) Nuevos derivados amino de urea ciclicos como inhibidores de quinasa
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
PE20081238A1 (es) Piperidinas sustituidas como antagonistas de hdm2
PE20080345A1 (es) Derivados de piperazina como agonistas del receptor de gpr38
AR055563A1 (es) Compuestos de piridil acido acetico, agente farmaceutico y utilizacion del compuesto para preparar dicho agente
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed